SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Peginterferon Alfa-2b Powder Formulation

Version 2.11 Revision Date: 09/13/2019 SDS Number: 20518-00017 Date of last issue: 2019/05/03
Date of first issue: 2014/10/09

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Peginterferon Alfa-2b Powder Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 199 Wenhai North Road HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone : 908-740-4000
Emergency telephone number : 86-571-87268110
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

<table>
<thead>
<tr>
<th>Appearance</th>
<th>powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>White to light yellow</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
</tbody>
</table>

May damage fertility. May damage the unborn child.

GHS Classification
Reproductive toxicity : Category 1B

GHS label elements
Hazard pictograms : ☑

Signal word : Danger
Hazard statements : H360FD May damage fertility. May damage the unborn child.
Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/

1 / 12
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Peginterferon Alfa-2b Powder Formulation

Version 2.11  Revision Date: 09/13/2019  SDS Number: 20518-00017  Date of last issue: 2019/05/03
Date of first issue: 2014/10/09

attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
May damage fertility. May damage the unborn child.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components
<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>&gt;= 90 -&lt;= 100</td>
</tr>
<tr>
<td>Peginterferon Alfa-2b</td>
<td>215647-85-1</td>
<td>&gt;= 0.3 -&lt; 1</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and : May damage fertility. May damage the unborn child.
Contact with dust can cause mechanical irritation or drying of
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Peginterferon Alfa-2b Powder Formulation

Version 2.11
Revision Date: 09/13/2019
SDS Number: 20518-00017
Date of last issue: 2019/05/03
Date of first issue: 2014/10/09

Protection of first-aiders:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during firefighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Metal oxides
- Phosphorus compounds
- Oxides of phosphorus
- Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and dis-
posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling
Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Peginterferon Alfa-2b</td>
<td>215647-85-1</td>
<td>TWA (inhalable fraction)</td>
<td>0.2 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Peginterferon Alfa-2b Powder Formulation

Engineering measures
Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment
Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type
Particulates type

Eye/face protection
Wear the following personal protective equipment:
Safety goggles

Skin and body protection
Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hand protection
Material
Chemical-resistant gloves

Remarks
Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Hygiene measures
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance
powder

Colour
White to light yellow

Odour
No data available

Odour Threshold
No data available

pH
No data available

Melting point/freezing point
No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.

Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available
**Peginterferon Alfa-2b Powder Formulation**

**Conditions to avoid**
- Heat, flames and sparks.
- Avoid dust formation.

**Incompatible materials**
- Oxidizing agents

**Hazardous decomposition products**
- No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

**Exposure routes**
- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**
Not classified based on available information.

#### Components:

**Sucrose:**
Acute oral toxicity: LD50 (Rat): 29,700 mg/kg

**Peginterferon Alfa-2b:**
Acute toxicity (other routes of administration): LD50 (Rat): > 20.1 mg/kg
- Application Route: Intravenous
- LD50 (Monkey): > 9.8 mg/kg

**Skin corrosion/irritation**
Not classified based on available information.

#### Components:

**Peginterferon Alfa-2b:**
Species: Rabbit
Result: Mild skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

#### Components:

**Peginterferon Alfa-2b:**
Species: Rabbit
Result: Mild eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.
Germ cell mutagenicity
Not classified based on available information.

**Components:**

**Sucrose:**
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test  
Result: negative

**Peginterferon Alfa-2b:**
Genotoxicity in vitro: Test Type: reverse mutation assay  
Result: negative  
Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo: Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage fertility. May damage the unborn child.

**Components:**

**Peginterferon Alfa-2b:**
Effects on fertility: Test Type: Fertility/early embryonic development  
Species: Monkey, female  
Application Route: Subcutaneous  
Dose: 0.35 milligram per kilogram  
Symptoms: Effect on estrous cycle

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
Not classified based on available information.

**Components:**

**Peginterferon Alfa-2b:**
Target Organ: Gastrointestinal tract, Immune system, Cardio-vascular system, Endocrine system, Central nervous system, Liver, Respiratory Tract, Eye

Assessment: Causes damage to organs through prolonged or repeated
Repeated dose toxicity

**Components:**

**Peginterferon Alfa-2b:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.0038 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>9 d</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.0042 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>0.12 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Blood, Bone marrow, Immune system</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.015 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.077 mg/kg</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Respiratory Tract, Cardio-vascular system, Central nervous system, Bone marrow</td>
</tr>
</tbody>
</table>

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

**Components:**

**Peginterferon Alfa-2b:**

Inhalation : Symptoms: flu-like symptoms, Gastrointestinal disturbance, mental depression, tingling

12. ECOLOGICAL INFORMATION

Ecotoxicity

**Components:**

**Peginterferon Alfa-2b:**

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available
Persistence and degradability

Components:

Peginterferon Alfa-2b:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 63 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Sucrose:
Partition coefficient: n-octanol/water: Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations
GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Peginterferon Alfa-2b Powder Formulation

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

- AICS : not determined
- DSL : not determined
- IECSC : not determined

16. OTHER INFORMATION

Further information
Sources of key data used to compile the Safety Data Sheet

Date format : yyyy/mm/dd

Full text of other abbreviations
- ACGIH : USA. ACGIH Threshold Limit Values (TLV)
- ACGIH / TWA : 8-hour, time-weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoG - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evalua-
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Peginterferon Alfa-2b Powder Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.11</td>
<td>09/13/2019</td>
<td>20518-00017</td>
<td>2019/05/03</td>
<td>2014/10/09</td>
</tr>
</tbody>
</table>

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN